News on molecular diagnostics, pharmacogenomics tests for coronary artery disease, congenital heart defects, and more.
The Toronto-based molecular diagnostics maker also plans to enter applied markets in the near term, and ultimately point-of-care infectious disease testing.
Nine of the genes analyzed had limited or disputed evidence linking them to long QT syndrome, suggesting they should not be included in genetic testing panels.
The Milwaukee, Wisconsin-based firm is part of a growing biotech ecosystem in the region, which has particular expertise in transplant medicine.
Ongoing Scripps research into polygenic risk for coronary artery disease now offers remote genetic counseling as well as an Android app.
A genome-wide association meta-analysis involving almost one million heart failure cases and controls identified 11 risk loci and helped distinguish potential causal contributors.
